Market News AIOpen the app

Regeneron is using a new combined system with SAS and Posit to improve its clinical development work.

MarketRead the original at prnewswire.com
Good for REGN

Regeneron combined SAS and open-source tools in one workflow, removing workarounds, data copying, and duplicate access checks. This should smooth clinical work, though the report gives no time or cost savings.

REGN · Regeneron Pharmaceuticals, Inc.

AI read · Good for REGN

The AI's read

Removing repeated data handling and separate access checks should make clinical study work easier. Teams can also use AI within secure controls. The report gives no time or cost savings, so the size of the gain is not shown.

Get alerts for REGN

Follow Regeneron Pharmaceuticals, Inc. (REGN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for REGN
Free on the App Store and Google Play, or on the web.